Novavax, Inc.

Novavax, Inc. is a global biotechnology company dedicated to the discovery, development, and commercialization of innovative vaccines designed to prevent serious infectious diseases. Leveraging a proprietary vaccine platform, Novavax combines cutting-edge recombinant protein technology with advanced nanoparticle formulation and its patented Matrix-M adjuvant. This unique approach is engineered to significantly enhance the immune response, offering robust protection against a range of challenging pathogens. The company has successfully brought its COVID-19 vaccine, NVX-CoV2373, to market under various brand names including Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted, serving as a primary immunization series and a booster for both homologous and heterologous applications in adult and adolescent populations. Beyond its COVID-19 offering, Novavax is actively advancing a promising malaria vaccine candidate, R21/Matrix-M adjuvant, addressing a critical global health need. With a strategic focus on addressing unmet medical needs through scientific excellence, Novavax aims to become a leading force in vaccine innovation, contributing to global public health security.